Last reviewed · How we verify
H.P. ACTHAR GEL (REPOSITORY CORTICOTROPIN)
H.P. ACTHAR GEL (generic name: REPOSITORY CORTICOTROPIN) is a Adrenocorticotropic Hormone [EPC] drug developed by QUESTCOR PHARMA. It is currently FDA-approved.
H.P. ACTHAR GEL is a repository corticotropin injection that acts as an agonist to the adrenocorticotropic hormone receptor, specifically activating the melanocorticin receptor 2. It is used to treat various conditions, including autoimmune diseases, dry eye, neurotrophic keratitis, sarcoidosis, and hypercalcemia due to sarcoidosis, as indicated by clinical trials.
At a glance
| Generic name | REPOSITORY CORTICOTROPIN |
|---|---|
| Sponsor | QUESTCOR PHARMA |
| Drug class | Adrenocorticotropic Hormone [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Hypertension
- Headache
- Weight gain
- Increased sweating
- Acne
- Menstrual irregularities
- Development of Cushingoid state
- Sodium retention
- Fluid retention
- Muscle weakness
- Nausea
- Vomiting
Serious adverse events
- Peptic ulcer with possible perforation and hemorrhage
- Pancreatitis
- Congestive heart failure
- Convulsions
- Increased intracranial pressure with papilledema
- Anaphylaxis
- Aseptic necrosis of femoral and humeral heads
- Vertebral compression fractures
- Necrotizing angiitis
- Glaucoma with possible damage to optic nerve
Key clinical trials
- ACTHAR Therapy for Central Nervous System Sarcoidosis (Phase 4)
- Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Rando (Phase 2)
- Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis (NA)
- Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous (Phase 2)
- Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis (Phase 4)
- A Multicenter, Open-label Study to Assess the Efficacy and Safety of Acthar® Gel in Subjects With Severe Keratitis (Phase 4)
- A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis (Phase 2)
- A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Act (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H.P. ACTHAR GEL CI brief — competitive landscape report
- H.P. ACTHAR GEL updates RSS · CI watch RSS
- QUESTCOR PHARMA portfolio CI
Frequently asked questions about H.P. ACTHAR GEL
What is H.P. ACTHAR GEL?
Who makes H.P. ACTHAR GEL?
What is the generic name of H.P. ACTHAR GEL?
What drug class is H.P. ACTHAR GEL in?
What development phase is H.P. ACTHAR GEL in?
What are the side effects of H.P. ACTHAR GEL?
Related
- Drug class: All Adrenocorticotropic Hormone [EPC] drugs
- Manufacturer: QUESTCOR PHARMA — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing